AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

Nvidia's Q2 FY2025 results were strong, but Q3 may not exceed forecasts significantly, leading to a potential stock price ...

Declining inflation and potential changes in low-wage labor dynamics pose risks to Walmart's future performance. Read more on ...

Rolls-Royce's recent trading update continues to reflect progress. The stock's forward P/E also continues to reflect upside ...

IonQ aims to lead the quantum networking market with two key milestones achieved this year. Read more about IONQ stock here.

Aurora Cannabis sees 29% YoY growth and solid cash flow, unaffected by U.S. market fears. Read why ACB stock remains a solid ...

WeRide Inc. (WRD), a Chinese autonomous vehicle startup, saw a 28% jump in stock price post-IPO, reaching a market cap over ...

Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...

Robinhood Markets, Inc.'s surging post-election share price is met with skepticism due to overvaluation. Learn more about ...

Energy Transfer sees growth in oil and natural gas, boosted by new demand. See why ET stock offers low volatility gains and ...

We can clearly see that the BlackRock Floating Rate Income Trust is not the highest-yielding fund in this peer grouping.

Rayonier has made good progress with its asset divestment plan, and the stock has good valuation re-rating potential. Learn ...